Status:
COMPLETED
Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?
Lead Sponsor:
University of Dundee
Collaborating Sponsors:
Chief Scientist Office of the Scottish Government
NHS Tayside
Conditions:
Chronic Obstructive Pulmonary Disease
Pulmonary Hypertension
Eligibility:
All Genders
35-85 years
Phase:
PHASE2
Brief Summary
The investigators hypothesise that phosphodiesterase 5A inhibitors will improve exercise capacity in those with Chronic Obstructive Pulmonary Disease and secondary pulmonary hypertension.
Eligibility Criteria
Inclusion
- COPD
- Forced expiratory volume in 1 second (FEV1) \<80% (FEV1/FVC \<0.70)
- Right ventricular systolic pressure (RVSP) \> 30 mmHg or Pulmonary Acceleration time \<120 ms
Exclusion
- Pulmonary stenosis or echo left ventricular outflow tract obstruction
- Left ventricular ejection fraction \< 45%
- Patients taking nitrates, nicorandil or doxazosin.
- Drug contraindications:
- Systolic Blood Pressure \<90 mmHg
- recent stroke
- unstable angina
- past history of non arteritic anterior ischaemic optic neuropathy
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT01197469
Start Date
September 1 2010
End Date
September 1 2012
Last Update
November 6 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Dundee
Dundee, Tayside, United Kingdom, DD1 9SY